IBIO
$2.46
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Recent News
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio Insiders Placed Bullish Bets Worth US$655.0k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
BC-Most Active Stocks
Nu Holdings Ltd. 30,054,902 16.85
iBio, Inc. (IBIO) Reports Q1 Loss
iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?